Skip to content

Association Between Female Hormonal Profile and Wound Healing

Association Between Female Hormonal Profile and Wound Healing Outcomes After Reduction Mammaplasty

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07724145
Acronym
FEMHEAL
Enrollment
84
Registered
2026-07-23
Start date
2026-07-01
Completion date
2028-12-01
Last updated
2026-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Estradiol, Wound Healing, Wound Healing Complication

Keywords

wound healing, menstrual cycle, estradiol, hormones, dehiscence, reduction mammaplasty

Brief summary

The goal of this observational study is to assess the relationship between female hormonal status and postoperative wound healing in reduction mammaplasty. The main questions it aims to answer are: 1. Does wound healing differ depending on whether the operation takes place before or after ovulation in the menstrual cycle? 2. Does estradiol have a positive effect on wound healing? Participants with mammary hypertrophy will undergo reduction mammaplasty, and the investigators will measure their hormonal profile (LH, FSH, and estradiol) on the day of surgery.

Detailed description

The study will be designed as a prospective, observational, single-center investigation including 84 cisgender female patients aged 18 years or older, presenting with a clear medical indication for reduction mammaplasty. The preoperative evaluation will include standard physical assessment and confirmation of coverage by the patient's health insurance provider. Patients with a history of breast cancer, active tobacco use, corticosteroid or contraceptive intake, will be excluded from participation. The surgical procedure will be performed by a senior plastic surgeon under general anesthesia, following gold-standard technical and safety guidelines. On the day of surgery, peripheral blood samples will be collected for the measurement of serum estradiol, progesterone, and luteinizing hormone (LH) concentrations. Postoperative wound care will be standardized, using Dermabond Prineo medical adhesive dressing maintained in place for 21 days. The primary endpoint will be defined as complete wound healing at postoperative day 21. To standardize the assessment and improve its reproducibility, "complete healing" is defined as a wound that no longer requires any dressing care and can be left exposed to air. Wound healing outcomes will be correlated and analyzed in relation to serum hormone levels measured on the day of surgery. Standard postoperative follow-up visits will be scheduled at 48 hours, 7 days, 21 days, 6 weeks, and at 3-, 6-, and 12-months post-surgery.

Interventions

None listed

Sponsors

University Hospital, Geneva
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Symptomatic breast hypertrophy * Premenopausal

Exclusion criteria

* Previous breast reduction surgery * Menopausal status * Oral contraceptives * Corticosteroid therapy * History of breast cancer * Active smoking and use of nicotine substitution products

Design outcomes

Primary

MeasureTime frameDescription
Wound healing at 21 days postoperative21 daysComplete wound healing at day 21 will be evaluated in all patient groups and correlated with serum estradiol levels measured on the day of surgery. At this time point, complete healing is defined as a closed, fully epithelialized scar with only mild residual inflammation and no need for further dressings. Persistent crusting, discharge, or dehiscence exposing dermis or subcutaneous tissue will be classified as delayed healing and managed with continued dressing care. For consistency, "complete healing" is operationally defined as a wound that no longer requires any dressing and can remain exposed to air, and results will be documented using standardized photographs.

Secondary

MeasureTime frameDescription
Wound dehiscence21 daysComplete wound healing at day 21 will be evaluated in all patient groups and correlated with serum estradiol levels measured on the day of surgery. At this time point, complete healing is defined as a closed, fully epithelialized scar with only mild residual inflammation and no need for further dressings. Persistent crusting, discharge, or dehiscence exposing dermis or subcutaneous tissue will be classified as delayed healing and managed with continued dressing care. For consistency, "complete healing" is operationally defined as a wound that no longer requires any dressing and can remain exposed to air, and results will be documented using standardized photographs.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 24, 2026